Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer ...
It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
C. Michael White, University of Connecticut (THE CONVERSATION) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion ...
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...